Stifel analyst Jonathan Block said Medtronic’s 4QF18 Diabetes division results are encouraging for Intricon Corp (NASDAQ: IIN).Block highlights that diabetes ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Medtronic, Inc. (MDT) PT Raised to $95 at Morgan StanleyMay 25, 2018 7:49 AM Medtronic, Inc. (MDT) PT Raised to $95 at RBC CapitalMay 25, 2018 6:39 AM Medtronic, Inc. (MDT) PT Raised to $97 at Needham & CompanyMay 24, 2018 5:12 PM Medtronic, Inc. (MDT) PT Raised to $87 at StifelMay 24, 2018 2:13 PM